HPV vaccine for adolescent males: Acceptability to parents post-vaccine licensure

Vaccine

Volumn 28, Issue 38, 2010, Pages 6292-6297

  Reiter, Paul L ^a,b   McRee, Annie Laurie ^a   Gottlieb, Sami L ^c   Brewer, Noel T ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Acceptability; HPV vaccine; Males

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; DRUG APPROVAL; DRUG COST; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATERNAL ATTITUDE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; CHILD; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; MOTHERS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 77955660811     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.114     Document Type: Article

References (37)

1. Cates W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999, 26(4 Suppl.):S2-7.
2. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006, 194(8):1044-1057.
3. Nielson C.M., Harris R.B., Dunne E.F., Abrahamsen M., Papenfuss M.R., Flores R., et al. Risk factors for anogenital human papillomavirus infection in men. J Infect Dis 2007, 196(8):1137-1145.
4. Partridge J.M., Hughes J.P., Feng Q., Winer R.L., Weaver B.A., Xi L.F., et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007, 196(8):1128-1136.
5. Giuliano A.R., Lu B., Nielson C.M., Flores R., Papenfuss M.R., Lee J.H., et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008, 198(6):827-835.
6. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3). S3/11-25.
7. Watson M., Saraiya M., Ahmed F., Cardinez C.J., Reichman M.E., Weir H.K., et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 2008, 113(10 Suppl.):2841-2854.
8. Brown D.R., Schroeder J.M., Bryan J.T., Stoler M.H., Fife K.H. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999, 37(10):3316-3322.
9. Lacey C.J., Lowndes C.M., Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24(Suppl. 3). S3/35-10.
10. Dinh T.H., Sternberg M., Dunne E.F., Markowitz L.E. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008, 35(4):357-360.
11. Bosch F.X., Castellsague X., Munoz N., de Sanjose S., Ghaffari A.M., Gonzalez L.C., et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996, 88(15):1060-1067.
12. Habel L.A., Van Den Eeden S.K., Sherman K.J., McKnight B., Stergachis A., Daling J.R. Risk factors for incident and recurrent condylomata acuminata among women. A population-based study. Sex Transm Dis 1998, 25(6):285-292.
13. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24.
14. Merck and Co. Inc. Gardasil prescribing information; 2009. Available at: http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf.
15. Giuliano A, Palefsky J, on behalf of the male quadrivalent HPV vaccine efficacy trial study group. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. Abstract of presentation at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference. Nice, France. November 2008, http://www.eurogin.com/.
16. Palefsky J, Giuliano A, on behalf of the male quadrivalent HPV vaccine efficacy trial study group. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. Abstract of presentation at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference. Nice, France. November 2008, http://www.eurogin.com/.
17. Centers for Disease Control and Prevention. ACIP provisional recommendations for HPV vaccine; 2009. Available at: http://www.cdc.gov/vaccines/recs/provisional/downloads/hpv-vac-dec2009-508.pdf.
18. Centers for Disease Control and Prevention FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(20):630-632.
19. Liddon N., Hood J., Wynn B.A., Markowitz L.E. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 2010, 46(2):113-123.
20. Podolsky R., Cremer M., Atrio J., Hochman T., Arslan A.A. HPV vaccine acceptability by Latino parents: a comparison of U.S. and Salvadoran populations. J Pediatr Adolesc Gynecol 2009, 22(4):205-215.
21. The American Association for Public Opinion Research Standard definitions: final dispositions of case codes and outcome rates for surveys 2009, AAPOR. 6th ed.
22. Keating K.M., Brewer N.T., Gottlieb S.L., Liddon N., Ludema C., Smith J.S. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health 2008, 43(4 Suppl.):S61-S67.
23. Fazekas K.I., Brewer N.T., Smith J.S. HPV vaccine acceptability in a rural Southern area. J Womens Health (Larchmt) 2008, 17(4):539-548.
24. Reiter P.L., Brewer N.T., Gottlieb S.L., McRee A.L., Smith J.S. Parents' health beliefs and HPV vaccination of their adolescent daughters. Soc Sci Med 2009, 69(3):475-480.
25. Office of Management and Budget. Standards for defining metropolitan and micropolitan statistical areas; notice. Federal Register; 65(249):82227-38. December 27; 2000. Available at: http://www.whitehouse.gov/omb/fedreg/metroareas122700.pdf.
26. Watts L.A., Joseph N., Wallace M., Rauh-Hain J.A., Muzikansky A., Growdon W.B., et al. HPV vaccine: a comparison of attitudes and behavioral perspectives between Latino and non-Latino women. Gynecol Oncol 2009, 112(3):577-582.
27. Slomovitz B.M., Sun C.C., Frumovitz M., Soliman P.T., Schmeler K.M., Pearson H.C., et al. Are women ready for the HPV vaccine?. Gynecol Oncol 2006, 103(1):151-154.
28. Gerend M.A., Weibley E., Bland H. Parental response to human papillomavirus vaccine availability: uptake and intentions. J Adolesc Health 2009, 45(5):528-531.
29. Centers for Disease Control and Prevention (CDC) National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2009, 58(36):997-1001.
30. Brewer N.T., Fazekas K.I. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007, 45(2-3):107-114.
31. Gerend M.A., Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis 2009, 36(1):58-62.
32. Jones M., Cook R. Intent to receive an HPV vaccine among university men and women and implications for vaccine administration. J Am Coll Health 2008, 57(1):23-32.
33. McRee AL, Reiter PL, Chantala K, Brewer NT. The influence of disease outcome framing on HPV vaccine acceptability among men. Cancer Epidemiol Biomarkers Prev; in press.
34. Constantine N.A., Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 2007, 40(2):108-115.
35. Markowitz L.E., Sternberg M., Dunne E.F., McQuillan G., Unger E.R. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009, 200(7):1059-1067.
36. Baker LC, Bundorf MK, Singer S, Wagner TH. Validity of the survey of health and internet and Knowledge Network's panel and sampling; 2003. Available at: http://www.knowledgenetworks.com/ganp/docs/Appendix%2520Survey%2520of%2520Health%2520and%2520the%2520Internet.pdf.
37. Dennis JM. Description of within-panel survey sampling methodology: the Knowledge Networks approach; 2009. Available at: http://www.knowledgenetworks.com/ganp/docs/KN-Within-Panel-Survey-Sampling-Methodology.pdf.